• Journal of the Korea Convergence Society
• /
• v.12 no.8
• /
• pp.179-186
• /
• 2021

Among the Covid-19 vaccine platforms, mRNA-platform vaccines are summarized qualitatively in this paper. Manufacturing mRNA vaccines consist of serial processes; the preparation process of DNA template, the transcription of mRNA, nanoemulsion process, and the fill and finish unit combined with formulation stages. It is noticeable that major players are collaborated for producing mRNA vaccines. In particular, the nanoemulsion process is recognized to the key process requiring formulated lipid materials to protect modified mRNA until they arrive in intracellular cytosol. It is known that the nanoemulsion process adapts well-designed microfluidic devices. We expect that the nanoemulsion process will stimulate pharmaceutical industries to develop diverse applications.

• Journal of Life Science
• /
• v.33 no.9
• /
• pp.746-753
• /
• 2023

Viral infectious diseases have been regarded as one of the greatest threats to global public health. The recent coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a stark reminder of the threat posed by emerging viral infections. Developing and producing appropriate and efficient vaccines and therapeutics are the only options to combat this pandemic. The COVID-19 pandemic has highlighted the need for novel vaccine platforms to control and prevent emerging viral diseases. Conventional vaccine platforms, including live-attenuated vaccine and inactivated vaccines, pose limitations in the speed of vaccine development, manufacturing capacity, and broad protection for emergency use. Interestingly, vaccination with the SARS-CoV-2 vaccine candidate based on the mRNA-lipid nanoparticle (LNP) platform protected against COVID-19, confirming that the nucleoside-modified candidate is a safe and effective alternative to conventional vaccines. Moreover, the prophylactic strategies against the COVID-19 pandemic have been mRNA nucleic acid-based vaccines and nanoparticle-based platforms, which are effective against SARS-CoV-2 and its variants. Overall, the novel vaccine platform has presented advantages compared with the traditional vaccine platform in the COVID-19 pandemic. This review explores the recent advancements in vaccine technologies and platforms, focusing on mRNA vaccines, digital vaccines, and nanoparticles while considering their advantages and possible drawbacks.

• Journal of the korean veterinary medical association
• /
• v.17 no.2
• /
• pp.33-41
• /
• 1981

뉴캣슬병 바이러스가 발견된지 50여년이 지난 오늘에도 그 발생은 전 세계적으로 광범위하다. NDV가 분리됨으로 백신개발이 이루어져 1930년대말부터 완전하지는 못했으나 그런대로 방역을 맡았으며 그후 개량발전된 백신으로 각국에서 예방접종하고 있으나 여전히 발생하고 있다. NDV는 Paramyxovirus로서 RNA를 가지고 있으며 크기는 $100\~600{\mu}m$ 범위의 크기와 lipoprotein envelope로 쌓여 있다. 분리동정에 이용되는 혈구응집소, neuraminidase의 작용, 용혈성 등 모두 envelope와 관련이 있으며 이와 관련된 연구가 많이 진행되고 있다. NDV가 세포에 침투하는 과정에서 특이한 receptor에 부착하여 envelope의 용해 및 nucleocapsid의 세포속에 침투 등이 밝혀지고 있으며 NDV의 Virion은 RNA의존 RNA 복합체를 가지고 있고 보족 RNA는 바이러스 단백질 및 RNA를 산생하기 위해서 숙주에 의하여 전환을 한다. 1 일령추의 뇌내접종, 정맥내 접종 및 계태 아치사시간 등의 방법으로 Velogenic, Mesogenic Lentogenic type으로 분류하고 감염력에 따라 Virulent 또는 avirulent로 구분된다. 국내에서 분리된 NDV는 현재 Velogenic형으로 분류되고 있으나 앞으로 지역별, 계절별, 감염된 숙주별로 광범위하게 분리하여 국내에서 유행하고 있는 NDV의 성상조사와 특성을 파악 할 필요성이 요청된다.

• Proceedings of the Korea Society of Poultry Science Conference
• /
• 2004.11a
• /
• pp.23-25
• /
• 2004

This study was conducted to investigate the effects of dietary supplementation of Ecklonia cava kjellman(ECK) and crude lectin extracted from ECK (CLEEC) on performances and immune responses in broiler chicks. A total of two hundreds thirty four 1 day old male broiler chicks (Ross) were fed corn-soy based diets containing 0 % (with or without vaccination and Salmonella challenge), 1.0 % ECK, 0.05 %, 0.1 % and 0.3 % CLEEC for 38 days and vaccinated against inactivated ND-IB combined oil vaccine on the fourth day. After S. gallinarum challenge. mortality was measured daily. The spleens of birds were removed for RNA extraction and reverse transcription polymerase chain reaction (RT-PCR) with primer sets for IFN-ν, IL-2, IL-6 and ${\beta}$-actin were performed with RNA samples. At the 28th day, pancreas weights were heavier 0.3 % CLEEC than 1.0 % ECK group. At the 21st day after ND-IB oil vaccine injection, dietary supplementation of ECK and CLEEC tended to increase or significantly (P<0.05) improved ND or IB titer compared to the positive control. Mortality was significantly (P<0.05) decreased by dietary CLEEC treatments. Chicken splenic IFN-ν, IL-2, and IL-6 cytokines mRNA expressions were enhanced by challenge with S, gallinarum. Dietary treatments did not affect mRNA expression of IFN-ν. However, IL-2 and IL-6 expressions in Salmonella challenged birds that fed the 1.0 % ECK or 0.05 % CLEEC groups were enhanced (P<0.05) compare to the positive control. The results demonstrated that dietary ECK and CLEEC enhanced humoral and cellular immunity and therefore. it can be concluded that dietary supplementation of ECK and CLEEC can be used as a feed additive for enhancement of immunocompetence without any adverse effects in broiler chicks.

• Pediatric Infection and Vaccine
• /
• v.29 no.1
• /
• pp.37-45
• /
• 2022

Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, we conducted a Delphi survey that included the experts from the field of COVID-19 immunization in children aged 5-11 years. The aim was to organize collective expert opinions on COVID-19 vaccination in young children in the Republic of Korea, and so thus assist the vaccination policy. Methods: The panels included pediatric infectious disease specialists, preventive medicine experts, infectious disease physicians, and COVID-19 vaccine experts consulting the Ministry of Health and Welfare. The Delphi survey was conducted online using a questionnaire from February 14 to February 27, 2022. Results: The Delphi panels agreed that children were vulnerable to COVID-19, and the severity of illness was modest. Furthermore the panels reported that children with chronic illness were more susceptible to a worsening clinical course. There were generally positive opinions on the effectiveness of COVID-19 vaccination in children aged 5-11 years, and experts gathered a slightly positive opinion that the adverse events of pediatric COVID-19 were not numerous. The benefits of COVID-19 vaccination were evaluated at a level similar to the potential risks in children. Currently, the only approved mRNA platform vaccine in children seemed to be sustainable; however, the recombinant protein platform COVID-19 vaccines were evaluated as better options. Conclusions: Due to the surge of the Omicron variant and an increase in pediatric cases, the COVID-19 vaccination in young children may have to be considered. Panels had neutral opinions regarding the COVID-19 vaccination in children aged 5-11 years. Thus monitoring of the epidemiology and the data about the safety of COVID-19 vaccination should be continued.

• Herbal Formula Science
• /
• v.30 no.4
• /
• pp.363-373
• /
• 2022

Objectives : The purpose of this study is to report one case of Korean medical treatment on a patient with psoriasis which had deteriorated since COVID-19 mRNA vaccination. Methods : A patient with psoriasis was treated with herbal medicine, acupuncture, and moxibustion. Symptoms after vaccination were considered the main criteria for treatment. PASI, DLQI, VAS, and pictures were used as evaluation tools for psoriasis. Results : After treatment, the patient showed improvements in PASI, DLQI and VAS scores. PASI changed from 16 to 0, DLQI changed from 17 to 0, and VAS changed from 8 to 0. Conclusions : The findings of this case report suggest that Korean medicine may be an effective option for treating psoriasis after COVID-19 mRNA vaccination.

• Pediatric Infection and Vaccine
• /
• v.29 no.1
• /
• pp.28-36
• /
• 2022

Purpose: To evaluate the efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines in children aged 5-11 years, a rapid systematic review was conducted on published clinical trials of COVID-19 vaccines and studies that analyzed real-world data on adverse events after COVID-19 vaccination. Methods: A systematic search was conducted on medical literature in international (Ovid-MEDLINE) and pre-published literature databases (medRxiv), followed by handsearching up to January 4, 2022. We used terms including COVID-19, severe acute respiratory syndrome coronavirus 2, and vaccines, and the certainty of evidence was graded using the GRADE approach. Results: A total of 1,675 studies were identified, of which five were finally selected. Among the five studies, four consisted of data from clinical trials of each of the four types of COVID-19 vaccines (BNT162b2, mRNA-1273, CoronaVac, and BBIBP-CorV). The remaining study consisted of real-world data on the safety of the BNT162b2 vaccine in children aged 5-11 years. This systematic review identified that COVID-19 vaccines in recipients aged 5-11 years produced a favorable immune response, and were vaccines were effective against COVID-19. The safety findings for the BNT162b2 vaccine in children and early adolescents aged 5-11 years were similar to those data noted in the clinical trial. Conclusions: There is limited data on COVID-19 vaccines in children aged 5-11 years. Consequently continuous and comprehensive monitoring is necessary for the evaluation of the safety and effectiveness of the COVID-19 vaccines.

• Clinical and Experimental Vaccine Research
• /
• v.12 no.1
• /
• pp.60-69
• /
• 2023

Purpose: Although the fast development of safe and effective messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 has been a success, waning humoral immunity has led to the recommendation of booster immunization. However, knowledge of the humoral immune response to different booster strategies and the association with adverse reactions is limited. Materials and Methods: We investigated adverse reactions and anti-spike protein immunoglobulin G (IgG) concentrations among health care workers who received primary immunization with mRNA-1273 and booster immunization with mRNA-1273 or BNT162b2. Results: Adverse reactions were reported by 85.1% after the first dose, 94.7% after the second dose, 87.5% after a third dose of BNT162b2, and 86.0% after a third dose of mRNA-1273. They lasted for a median of 1.8, 2.0, 2.5, and 1.8 days, respectively; 6.4%, 43.6%, and 21.0% of the participants were unable to work after the first, second, and third vaccination, respectively, which should be considered when scheduling vaccinations among essential workers. Booster immunization induced a 13.75-fold (interquartile range, 9.30-24.47) increase of anti-spike protein IgG concentrations with significantly higher concentrations after homologous compared to heterologous vaccination. We found an association between fever, chills, and arthralgia after the second vaccination and anti-spike protein IgG concentrations indicating a linkage between adverse reactions, inflammation, and humoral immune response. Conclusion: Further investigations should focus on the possible advantages of homologous and heterologous booster vaccinations and their capability of stimulating memory B-cells. Additionally, understanding inflammatory processes induced by mRNA vaccines might help to improve reactogenicity while maintaining immunogenicity and efficacy.

• Tuberculosis and Respiratory Diseases
• /
• v.57 no.1
• /
• pp.25-31
• /
• 2004

Background : IFN-${\gamma}$ is the main effector mediator of the host immune response against Mycobacterium tuberculosis. Evaluating the IFN-${\gamma}$ gene expression in response to M. tuberculosis antigens may help in elucidating the host defense mechanism against M. tuberculosis and in the development of a vaccine. Methods : The IFN-${\gamma}$ mRNA expression in the lymphocytes obtained from pleural effusions from tuberculous pleurisy patients (TB-PLC) after in vitro stimulation with whole cell M. tuberculosis(H37Rv), purified protein derivatives(PPD), man-lipoarabinamman (man-LAM), ara-LAM and Antigen 85B(Ag85B) were evaluated. The degree of IFN-${\gamma}$ mRNA expression was determined by a semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method. Results : M. tuberculosis induced the expression of IFN-${\gamma}$ mRNA in the TB-PLC in time and dose dependent manners. The PPD and Ag85B induced high levels of IFN-${\gamma}$ mRNA expression in the TB-PLC. However, man-LAM inhibited IFN-${\gamma}$ mRNA expression in the TB-PLC, while ara-LAM did not. Conclusion : IFN-${\gamma}$ mRNA expression in TB-PLC is stimulated by PPD and Ag85B, but inhibited by man-LAM.

• Pediatric Infection and Vaccine
• /
• v.31 no.1
• /
• pp.12-24
• /
• 2024

The number of pediatric coronavirus disease 2019 (COVID-19) cases worldwide are increasing compared to the early phase of the pandemic, along with highly transmissible severe acute respiratory syndrome coronavirus variant and the increase in adult COVID-19 vaccination. We conducted a rapid systematic review and meta-analysis of published randomized clinical trials (RCTs) of the COVID-19 vaccines and the observational retrospective studies on adverse events after COVID-19 vaccination in adolescents. Seventeen studies were finally included in this systematic review. Meta-analysis showed that although vaccination in adolescents was significantly effective to prevent COVID-19 infection in retrospective studies (risk ratio [RR], 0.29; 95% confidence interval [CI], 0.22-0.37; I² =100%), however the effect of preventing COVID-19 infection was lower than in RCTs (RR, 0.05; 95% CI, 0.01-0.27). In five retrospective studies, the pooled estimated proportion of participants with myocarditis and/or pericarditis was 2.33 per 100,000 of the population (95% CI, 0.97-5.61 per 100,000). Sub-group analysis with sex and vaccine doses showed that male (5.35 per 100,000) and the second dose (9.71 per 100,000) had significantly higher incidence of myocarditis and/or pericarditis than female (1.09 per 100,000) and the first dose (1.61 per 100,000), respectively. Our study showed that mRNA COVID-19 vaccines in adolescent recipients were favorable and effective against COVID-19 in RCT as well as observational studies. The safety findings of BNT162b2 vaccine in adolescents were explored and we found the difference of safety according to sex and vaccine doses. The occurrence of adverse events after mRNA COVID-19 vaccination should be monitored.